CanSino Biologics Inc. (HKG: 6185)
Hong Kong
· Delayed Price · Currency is HKD
29.95
-0.10 (-0.33%)
Nov 15, 2024, 10:48 AM HKT
CanSino Biologics Revenue
CanSino Biologics had revenue of 263.65M CNY in the quarter ending September 30, 2024, with 76.09% growth. This brings the company's revenue in the last twelve months to 748.53M, up 48.86% year-over-year. In the year 2023, CanSino Biologics had annual revenue of 357.08M, down -65.49%.
Revenue (ttm)
748.53M CNY
Revenue Growth
+48.86%
P/S Ratio
8.62
Revenue / Employee
501.02K CNY
Employees
1,494
Market Cap
11.74B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCanSino Biologics News
- 1 year ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 2 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 2 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 2 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 2 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 2 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 2 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 2 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire